|

JYP0322 150 mg bid Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Guangzhou JOYO Pharma Co., Ltd1

Indications

  • Other Protocol Specified Criteria1
  • Protein Kinase Inhibitors1
  • Brain Neoplasms1
  • Lung Neoplasms1
  • Lung Cancer1

Other1 trial

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.